{"id":3238,"date":"2013-02-19T15:30:00","date_gmt":"2013-02-19T15:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/bokslutskommunike-2012\/"},"modified":"2013-02-19T15:30:00","modified_gmt":"2013-02-19T15:30:00","slug":"bokslutskommunike-2012","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/bokslutskommunike-2012\/","title":{"rendered":"BOKSLUTSKOMMUNIK\u00c9 2012"},"content":{"rendered":"<div class=\"mfn-preamble\"><strong>Fortsatt tillv\u00e4xt &#8211; nu p\u00e5 egna ben<\/strong><\/div>\n<\/p>\n<p><span><strong>FJ\u00c4RDE KVARTALET<\/strong><strong><br \/><\/strong><\/span><\/p>\n<ul>\n<li><span><\/span><span>Oms\u00e4ttnings\u00f6kningen var 10 procent i lokala valutor. F\u00f6rs\u00e4ljningen var den h\u00f6gsta n\u00e5gonsin f\u00f6r ett enskilt kvartal och uppgick till 14,7 MSEK (13,7*), motsvarande en \u00f6kning om 7 procent i SEK. <\/span><\/li>\n<li><span><\/span><span>R\u00f6relseresultatet f\u00f6re avskrivningar (EBITDA) uppgick till 0,6 MSEK (2,5*). Eng\u00e5ngskostnader ing\u00e5r om 2,7 MSEK. EBITDA exklusive eng\u00e5ngskostnader uppgick till 3,3 MSEK motsvarande en EBITDA marginal om 22 procent.<\/span><\/li>\n<li><span><\/span><span>Nettoresultatet uppgick till -0,8 MSEK, vilket gav ett resultat per aktie om -0,04 SEK. <\/span><\/li>\n<li><span><\/span><span>Kassafl\u00f6det fr\u00e5n den l\u00f6pande verksamheten var <\/span><span>1,7 MSEK. <\/span><\/li>\n<li><span><\/span><span>Den 1 oktober 2012 delades XVIVO Perfusion ut till Vitrolifes aktie\u00e4gare och XVIVO Perfusions aktie upptogs till handel p\u00e5 NASDAQ OMX First North med f\u00f6rsta handelsdag den 8 oktober.<\/span><span><\/span><\/li>\n<li><span><\/span><span>XVIVO Perfusion erh\u00f6ll under november f\u00f6rs\u00e4ljningsgodk\u00e4nnande f\u00f6r STEEN Solution\u2122 i Kanada. Den f\u00f6rsta kommersiella ordern av STEEN Solution<\/span><span>\u2122<\/span><span> fakturerades till Kanada under december m\u00e5nad.<\/span><\/li>\n<li><span><\/span><span>I oktober \u00e5terkom FDA med kompletterande fr\u00e5gor r\u00f6rande ans\u00f6kan om marknadsgodk\u00e4nnande f\u00f6r STEEN Solution<\/span><span>\u2122<\/span><span> p\u00e5 den amerikanska marknaden. Dessa fr\u00e5gor har behandlats och besvarats.<\/span><span><\/span><\/li>\n<li><span><\/span><span>Den kliniska studien i USA fortg\u00e5r enligt plan, med goda kliniska resultat, 32 av planerade 42 patienter transplanterade.<\/span><span><\/span><\/li>\n<li><span><\/span><span>Fortsatt mycket stort intresse fr\u00e5n kliniker i USA.<\/span><span><\/span><\/li>\n<li><span><\/span><span>Ytterligare tv\u00e5 st\u00e4mningar i USA inl\u00e4mnade mot Vitrolifes amerikanska dotterbolag r\u00f6rande <\/span><span><span>Perfadex<\/span><\/span><span>. Eftersom produkterna s\u00e5lts f\u00f6re utdelningen av XVIVO Perfusion \u00e4r XVIVO Perfusion inte skadest\u00e5ndsskyldigt och Vitrolife hanterar st\u00e4mningarna \u00e4ven framgent.<\/span><\/li>\n<\/ul>\n<p><span><strong>HEL\u00c5RET PRO FORMA*<\/strong><\/span><span><span><br \/><\/span><\/span><\/p>\n<ul>\n<li><span><\/span><span>Oms\u00e4ttnings\u00f6kningen var 18 procent i lokala valutor. F\u00f6rs\u00e4ljningen pro forma* f\u00f6r 2012 var 56,9 MSEK (48,1*). Detta motsvarar en oms\u00e4ttningstillv\u00e4xt om 18 procent i SEK.<\/span><\/li>\n<li><span><\/span><span>R\u00f6relseresultatet f\u00f6re avskrivningar (EBITDA) pro forma* uppgick till 8,3 MSEK (20,8*). EBITDA marginalen var 15 procent. Eng\u00e5ngskostnader ing\u00e5r om 8,6 MSEK. EBITDA exklusive eng\u00e5ngskostnader uppgick till 16,9 MSEK motsvarande en EBITDA marginal om 30 procent.<\/span><\/li>\n<li><span><\/span><span>Ans\u00f6kan om f\u00f6rs\u00e4ljningsgodk\u00e4nnande f\u00f6r STEEN Solution\u2122 i USA skickades i juli in till det amerikanska l\u00e4kemedelsverket, FDA. I oktober \u00e5terkom FDA med kompletterande fr\u00e5gor, vilka behandlades och besvarades.<\/span><\/li>\n<li><span><\/span><span>Ytterligare tv\u00e5 st\u00e4mningar i USA inl\u00e4mnade mot Vitrolifes amerikanska dotterbolag r\u00f6rande <\/span><span>Perfadex<\/span><span>. Eftersom produkterna s\u00e5lts f\u00f6re utdelningen av XVIVO Perfusion \u00e4r XVIVO Perfusion inte skadest\u00e5ndsskyldigt och Vitrolife hanterar st\u00e4mningarna \u00e4ven framgent.<\/span><\/li>\n<\/ul>\n<p><span><strong>V\u00c4SENTLIGA H\u00c4NDELSER EFTER \u00c5RETS UTG\u00c5NG<\/strong><\/span><\/p>\n<ul>\n<li><span><\/span><span>Lager och distribution av produkter f\u00f6r Europa\/Asien har tagits \u00f6ver i egen regi.<\/span><\/li>\n<li><span><\/span><span>FDA har i b\u00f6rjan p\u00e5 februari flaggat f\u00f6r kompletterande fr\u00e5gor kommer inom kort. P\u00e5 Xvivos svar p\u00e5 dessa fr\u00e5gor kommer FDA ha 75 dagar, det vill s\u00e4ga drygt tre m\u00e5nader, p\u00e5 sig att svara.<\/span><\/li>\n<\/ul>\n<p><span><span>G\u00f6teborg 19 februari 2013<\/span><\/span><\/p>\n<p><span><span>XVIVO Perfusion AB (publ)<br \/>Magnus Nilsson, VD<\/span><\/span><span><\/span><\/p>\n<p><span>*P<span>ro forma 2012 \u00e4r resultatr\u00e4kningen f\u00f6r Vitrolifes segment Transplantation f\u00f6r perioden januari till september 2012, som det redovisats i Vitrolifes rapportering, adderat med XVIVO Perfusions resultatr\u00e4kning f\u00f6r perioden oktober till december 2012. J\u00e4mf\u00f6relsetal 2011 \u00e4r Vitrolifes segment Transplantation s\u00e5 som det redovisats i Vitrolifes rapportering.<\/span><\/span><\/p>\n<div class=\"mfn-footer\">\n<p><span>F\u00f6r ytterligare information kontakta: <\/span><\/p>\n<p><span>Magnus Nilsson, VD, tel: 031-788 21 50, e-post: <a href=\"mailto:magnus.nilsson@xvivoperfusion.com\" rel=\"nofollow\">magnus.nilsson@xvivoperfusion.com<\/a><\/span><br \/><span>Christoffer Rosenblad, CFO, tel: 031-788 21 59, e-post: <a href=\"mailto:christoffer.rosenblad@xvivperfusion.com\" rel=\"nofollow\">christoffer.rosenblad@xvivoperfusion.com<\/a><br \/>F\u00f6r ytterligare information om Xvivo Perfusions verksamhet h\u00e4nvisas till bolagets hemsida, <a href=\"http:\/\/www.xvivoperfusion.com\" rel=\"nofollow\">www.xvivoperfusion.com<\/a><\/span><\/p>\n<p><span>Xvivo Perfusion\u00a0\u00e4r skyldigt att offentligg\u00f6ra informationen i detta pressmeddelande enligt lagen om v\u00e4rdepappersmarknaden och\/eller lagen om handel med finansiella instrument. Informationen l\u00e4mnades f\u00f6r publicering den\u00a019 februari 2013,\u00a0kl. 16:30.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Fortsatt tillv\u00e4xt &#8211; nu p\u00e5 egna ben FJ\u00c4RDE KVARTALET Oms\u00e4ttnings\u00f6kningen var 10 procent i lokala valutor. F\u00f6rs\u00e4ljningen var den h\u00f6gsta&#8230;<\/p>\n","protected":false},"template":"","class_list":["post-3238","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-sv","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-vpml","mfn-news-tag-mfn-report","mfn-news-tag-mfn-report-interim","mfn-news-tag-mfn-report-interim-q4"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BOKSLUTSKOMMUNIK\u00c9 2012 - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/bokslutskommunike-2012\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BOKSLUTSKOMMUNIK\u00c9 2012 - XVIVO\" \/>\n<meta property=\"og:description\" content=\"Fortsatt tillv\u00e4xt &#8211; nu p\u00e5 egna ben FJ\u00c4RDE KVARTALET Oms\u00e4ttnings\u00f6kningen var 10 procent i lokala valutor. F\u00f6rs\u00e4ljningen var den h\u00f6gsta...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/bokslutskommunike-2012\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/bokslutskommunike-2012\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/bokslutskommunike-2012\\\/\",\"name\":\"BOKSLUTSKOMMUNIK\u00c9 2012 - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2013-02-19T15:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/bokslutskommunike-2012\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/bokslutskommunike-2012\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/bokslutskommunike-2012\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BOKSLUTSKOMMUNIK\u00c9 2012\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BOKSLUTSKOMMUNIK\u00c9 2012 - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/bokslutskommunike-2012\/","og_locale":"en_US","og_type":"article","og_title":"BOKSLUTSKOMMUNIK\u00c9 2012 - XVIVO","og_description":"Fortsatt tillv\u00e4xt &#8211; nu p\u00e5 egna ben FJ\u00c4RDE KVARTALET Oms\u00e4ttnings\u00f6kningen var 10 procent i lokala valutor. F\u00f6rs\u00e4ljningen var den h\u00f6gsta...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/bokslutskommunike-2012\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/bokslutskommunike-2012\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/bokslutskommunike-2012\/","name":"BOKSLUTSKOMMUNIK\u00c9 2012 - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2013-02-19T15:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/bokslutskommunike-2012\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/bokslutskommunike-2012\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/bokslutskommunike-2012\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"BOKSLUTSKOMMUNIK\u00c9 2012"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3238","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3238"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}